{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"aGVHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"16.7"}]}],"title":"cGVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Percentage patients with acute or chronic GVHD.\n\nThe diagnosis of chronic GVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD.","groups":[{"description":"Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI (1x10\\^7 CD3+ cells/kg) over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.\n\nPentostatin: Given IV\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG000","title":"Group 1A (Pentostatin, DLI Dose Level 1)"},{"description":"Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI (3x10\\^7 CD3+ cells/kg) over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.\n\nPentostatin: Given IV\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG001","title":"Group 1B (Pentostatin, DLI Dose Level 2)"},{"description":"Patients receive treatment as in group 1A. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD.\n\nPentostatin: Given IV\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG002","title":"Group 2C (Pentostatin, DLI Dose Level 1, Add'l IS)"},{"description":"Patients receive treatment as in group 1B. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD.\n\nPentostatin: Given IV\n\nTherapeutic Allogeneic Lymphocytes: Given IV","id":"OG003","title":"Group 2D (Pentostatin, DLI Dose Level 2, Add'l IS)"}],"paramType":"NUMBER","populationDescription":"No subjects were enrolled onto Group 2D because the dose escalation was not triggered before the study closed to accrual.","reportingStatus":"POSTED","timeFrame":"1 year after DLI","title":"Incidence of GVHD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}